To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Summary
HR8129, a bill to establish a full risk ACO program under Medicare, is at early legislative stage (referred to committee). The bill accelerates the shift from fee-for-service to value-based care, structurally benefiting large insurers with Medicare Advantage exposure. $UNH, $HUM, $CNC, and $CVS are direct beneficiaries. The bill has 1 cosponsor and 2 committee referrals, indicating low momentum currently. Market data shows significant recent outperformance in these tickers: $CNC +54.91% and $UNH +41.6% over 30 days, suggesting investors are already pricing in this legislative tailwind.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8129 is an early-stage bill with 1 cosponsor and 2 committee referrals—low legislative momentum currently.
- 2.The bill structurally expands the full-risk Medicare ACO market, benefiting insurers already dominant in value-based care: UNH, HUM, CNC, CVS.
- 3.Market data shows strong recent outperformance in these tickers (30-day gains: CNC +54.91%, UNH +41.6%), indicating investors are pricing in favorable Medicare policy tailwinds.
- 4.No explicit funding is authorized; revenue impact depends on CMS rulemaking and provider participation rates in the new ACO program.
Market Implications
Real market data shows UnitedHealth Group (UNH) at $366.77, up 41.6% in 30 days and 3.75% in the last week, trading above its 50-week midpoint but below its 52-week high of $413.26. Humana (HUM) at $229.72 is up 35.86% in 30 days but remains well off its 52-week high of $315.35, suggesting room for further upside if the bill gains momentum. Centene (CNC) at $49.57, up 54.91% in 30 days and 27.33% in the last week, is the best performer in the group—this likely reflects expectations that CNC's Medicaid and dual-eligible exposure benefits most from risk-based contracting expansion. CVS Health (CVS) at $80.98, up 15.55% in 30 days, is approaching its 52-week high of $85.15. The divergence between strong insurance stock performance and weakness in healthcare services tickers like Labcorp (LH, -1.75% in 30 days) and IQVIA (IQV, -2.97% in 30 days) supports the thesis that the move is specific to managed care risk-bearing, not a broad healthcare rally. Investors should monitor committee assignments and hearing schedules; if the bill receives a markup date, it would increase probability and likely drive further upside in these tickers. If the bill stalls, current price levels may reflect peak near-term enthusiasm.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.
Medical Nutrition Therapy Act of 2026
To amend title XVIII of the Social Security Act to remove cost-sharing responsibilities for chronic care management services under the Medicare program.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.